RETINAPHARMA ANNOUNCES FDA-CLEARANCE OF TONOPACH FOR GLAUCOMA DETERMINATION

RetinaPharma announced it received 510(k) FDA clearance to market its TonoPach device that enables more accurate intra-ocular pressure (IOP) determinations in patients.

TonoPach provides for the unprecedented simultaneous determination of IOP and corneal thickness at the same location on the cornea. This allows for ophthalmologists to make an adjustment of the intra-ocular pressure to take into account the effects of corneal thickness.

The ability of the TonoPach to more accurately measure real IOP in patients with thinned corneas is of particular concern in patients whose corneas have been thinned as a result of excimer laser refractive surgery such as LASIK. TonoPach allows for correction by the ophthalmologist of the observed IOP based on measured corneal thickness at the exact point of IOP measurement.